New drug combo aims to shrink advanced cervical cancer
Disease control
Ongoing
This phase 2 trial is testing whether combining two immunotherapy drugs, dostarlimab and cobolimab, can shrink tumors or slow the growth of advanced cervical cancer that has spread or returned. About 66 participants with measurable disease will receive the drugs by IV. The main g…
Phase: PHASE2 • Sponsor: Meghan Shea • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC